SG11201704685TA - Substituted 2-anilinopyrimidine derivatives as egfr modulators - Google Patents
Substituted 2-anilinopyrimidine derivatives as egfr modulatorsInfo
- Publication number
- SG11201704685TA SG11201704685TA SG11201704685TA SG11201704685TA SG11201704685TA SG 11201704685T A SG11201704685T A SG 11201704685TA SG 11201704685T A SG11201704685T A SG 11201704685TA SG 11201704685T A SG11201704685T A SG 11201704685TA SG 11201704685T A SG11201704685T A SG 11201704685TA
- Authority
- SG
- Singapore
- Prior art keywords
- substituted
- egfr modulators
- anilinopyrimidine derivatives
- anilinopyrimidine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462090869P | 2014-12-11 | 2014-12-11 | |
| US201562166883P | 2015-05-27 | 2015-05-27 | |
| PCT/US2015/065286 WO2016094821A2 (en) | 2014-12-11 | 2015-12-11 | Substituted 2-anilinopyrimidine derivatives as egfr modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704685TA true SG11201704685TA (en) | 2017-07-28 |
Family
ID=56108380
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201909060S SG10201909060SA (en) | 2014-12-11 | 2015-12-11 | Substituted 2-anilinopyrimidine derivatives as egfr modulators |
| SG11201704685TA SG11201704685TA (en) | 2014-12-11 | 2015-12-11 | Substituted 2-anilinopyrimidine derivatives as egfr modulators |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201909060S SG10201909060SA (en) | 2014-12-11 | 2015-12-11 | Substituted 2-anilinopyrimidine derivatives as egfr modulators |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10590111B2 (en) |
| EP (1) | EP3229798A4 (en) |
| JP (2) | JP6709786B2 (en) |
| KR (1) | KR20170098865A (en) |
| CN (3) | CN112457298B (en) |
| AU (1) | AU2015360360B2 (en) |
| BR (1) | BR112017012272A2 (en) |
| CA (1) | CA2970185C (en) |
| CO (1) | CO2017006962A2 (en) |
| EA (1) | EA036453B1 (en) |
| HK (1) | HK1245634A1 (en) |
| IL (1) | IL252554A0 (en) |
| MX (1) | MX2017007664A (en) |
| PH (1) | PH12017501057A1 (en) |
| SG (2) | SG10201909060SA (en) |
| TW (1) | TWI618704B (en) |
| WO (1) | WO2016094821A2 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111170998B (en) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | Pyrimidine or pyridine compound, preparation method and medical application thereof |
| SG10201909060SA (en) * | 2014-12-11 | 2019-11-28 | Beta Pharma Inc | Substituted 2-anilinopyrimidine derivatives as egfr modulators |
| MX2018013602A (en) | 2016-05-11 | 2019-08-22 | Beta Pharma Inc | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers. |
| CN109311858B (en) | 2016-05-26 | 2021-12-03 | 里科瑞尔姆Ip控股有限责任公司 | EGFR inhibitor compounds |
| BR112018075823A2 (en) | 2016-06-17 | 2019-03-26 | Beta Pharma, Inc. | n- (2- (2- (dimethylamino) ethoxy) -4-methoxy-5 - ((4- (1-methyl-1h-indol-3-yl) pyrimidin-2-yl) amino) phenyl) pharmaceutical salts acrylamide and its crystalline forms |
| CN106243044A (en) * | 2016-06-30 | 2016-12-21 | 浙江大学 | Pyridine derivatives containing halo acrylamide side chain and preparation and application |
| WO2018019204A1 (en) * | 2016-07-26 | 2018-02-01 | 深圳市塔吉瑞生物医药有限公司 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity |
| SG11201911859QA (en) | 2017-06-16 | 2020-01-30 | Beta Pharma Inc | Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
| CN109503573A (en) * | 2017-09-14 | 2019-03-22 | 昆明圣加南生物科技有限公司 | 2- substituted anilinic pyrimidine derivatives and application thereof |
| CN107935995A (en) * | 2017-11-28 | 2018-04-20 | 中山大学 | A kind of new 2 anilino-pyrimidine derivative and its application in antitumor drug is prepared |
| CN108017633A (en) * | 2018-01-30 | 2018-05-11 | 天津大学 | N- [5- (pyrimidine -2- amino) -2,4- di-substituted-phenyls] -2- fluoropropenes amide derivatives and application |
| AU2019289176A1 (en) * | 2018-06-18 | 2020-12-24 | Oxford University Innovation Limited | Gremlin-1 antagonist for the prevention and treatment of cancer |
| TW202126305A (en) * | 2019-09-23 | 2021-07-16 | 美商貝達醫藥公司 | Treatment of egfr mutant-related cancers using a combination of egfr and cdk4/6 inhibitors |
| WO2021094379A1 (en) | 2019-11-12 | 2021-05-20 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| KR20220130190A (en) | 2020-01-20 | 2022-09-26 | 아스트라제네카 아베 | Epidermal growth factor receptor tyrosine kinase inhibitor for cancer treatment |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| WO2023287783A1 (en) * | 2021-07-13 | 2023-01-19 | ACEA Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| WO2023187037A1 (en) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| US20240116926A1 (en) | 2022-04-28 | 2024-04-11 | Astrazeneca Ab | Heteroaromatic compounds |
| WO2023209084A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| WO2024002938A1 (en) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| WO2024008929A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL150388A0 (en) * | 1999-12-24 | 2002-12-01 | Aventis Pharma Ltd | Azaindoles |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| KR101152162B1 (en) | 2006-12-08 | 2012-07-10 | 에프. 호프만-라 로슈 아게 | Substituted pyrimidines and their use as jnk modulators |
| WO2010059711A1 (en) * | 2008-11-18 | 2010-05-27 | Wisconsin Alumni Research Foundation | Sigma-1 receptor ligands and methods of use |
| EP2440559B1 (en) * | 2009-05-05 | 2018-01-10 | Dana-Farber Cancer Institute, Inc. | Egfr inhibitors and methods of treating disorders |
| CN103501612B (en) * | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | The compound that cell is bred in cancer caused by suppression EGF-R ELISA |
| EP3686193B1 (en) * | 2011-07-27 | 2022-03-02 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
| WO2013169401A1 (en) * | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| CN104860941B (en) | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4-disubstituted phenyl-1,5-diamine derivatives and use thereof, and pharmaceutical composition and medicinal composition prepared from 2,4-disubstituted phenyl-1,5-diamine derivative |
| PE20170268A1 (en) * | 2014-06-19 | 2017-04-21 | Ariad Pharma Inc | HETEROARYL COMPOUNDS FOR KINASE INHIBITION |
| CN106458969A (en) | 2014-08-25 | 2017-02-22 | 四川海思科制药有限公司 | (substituted phenyl) (substituted pyrimidine) amino derivative, preparation method therefor, and medication use |
| CN105461695B (en) * | 2014-09-29 | 2018-03-27 | 齐鲁制药有限公司 | Pyrimidine or pyrrolotriazine derivatives and its production and use |
| CN111170998B (en) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | Pyrimidine or pyridine compound, preparation method and medical application thereof |
| SG10201909060SA (en) * | 2014-12-11 | 2019-11-28 | Beta Pharma Inc | Substituted 2-anilinopyrimidine derivatives as egfr modulators |
-
2015
- 2015-12-11 SG SG10201909060S patent/SG10201909060SA/en unknown
- 2015-12-11 EA EA201790921A patent/EA036453B1/en unknown
- 2015-12-11 US US15/534,838 patent/US10590111B2/en active Active
- 2015-12-11 JP JP2017530208A patent/JP6709786B2/en active Active
- 2015-12-11 CN CN202011112986.3A patent/CN112457298B/en active Active
- 2015-12-11 CA CA2970185A patent/CA2970185C/en active Active
- 2015-12-11 AU AU2015360360A patent/AU2015360360B2/en active Active
- 2015-12-11 TW TW104141810A patent/TWI618704B/en not_active IP Right Cessation
- 2015-12-11 SG SG11201704685TA patent/SG11201704685TA/en unknown
- 2015-12-11 KR KR1020177019147A patent/KR20170098865A/en not_active Application Discontinuation
- 2015-12-11 CN CN201580067776.8A patent/CN108024993B/en active Active
- 2015-12-11 CN CN202011112988.2A patent/CN112375067B/en active Active
- 2015-12-11 WO PCT/US2015/065286 patent/WO2016094821A2/en active Application Filing
- 2015-12-11 EP EP15867768.2A patent/EP3229798A4/en not_active Ceased
- 2015-12-11 BR BR112017012272-3A patent/BR112017012272A2/en not_active IP Right Cessation
- 2015-12-11 MX MX2017007664A patent/MX2017007664A/en unknown
-
2017
- 2017-05-28 IL IL252554A patent/IL252554A0/en active IP Right Grant
- 2017-06-07 PH PH12017501057A patent/PH12017501057A1/en unknown
- 2017-07-11 CO CONC2017/0006962A patent/CO2017006962A2/en unknown
-
2018
- 2018-04-17 HK HK18104991.1A patent/HK1245634A1/en unknown
-
2020
- 2020-03-16 US US16/819,539 patent/US11414401B2/en active Active
- 2020-05-25 JP JP2020090467A patent/JP7181558B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1245634A1 (en) | Substituted 2-anilinopyrimidine derivatives as egfr modulators | |
| HK1255045A1 (en) | Substituted oxopyridine derivatives | |
| AU359521S (en) | Light | |
| AU359523S (en) | Light | |
| ZA201605332B (en) | Trpa1 modulators | |
| AU359522S (en) | Light | |
| AU359518S (en) | Light | |
| SG11201609205WA (en) | Heterocyclyl-butanamide derivatives | |
| GB201416352D0 (en) | Spirocyclic derivatives | |
| GB201416346D0 (en) | Spirocyclic derivatives | |
| PL3131898T3 (en) | Fluoroalkylfluorene derivatives | |
| PL3418273T3 (en) | Flavagline derivatives | |
| IL248773A0 (en) | Naphthyridinedione derivatives | |
| IL248629B (en) | Cycloalkyl-linked diheterocycle derivatives | |
| PL3097076T3 (en) | Novel cyp-eicosanoid derivatives | |
| PL3119744T3 (en) | 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives | |
| AU359519S (en) | Light | |
| AU359832S (en) | Light | |
| GB201416905D0 (en) | Light Bolb | |
| GB201400215D0 (en) | Modulators |